About: MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by WILLIAM K. OH & Philip W. Kantoff published October 1998 in Journal of Urology

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 1998 (uk) article scientifique publié en 1998 (fr) im Oktober 1998 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by WILLIAM K. OH & Philip W. Kantoff published October 1998 in Journal of Urology (en)
publication date	wds:Q60156373-2A86D42C-5124-4882-A053-15B4CFC25E21
publication date	1998-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q60156373-36F8D4A3-7624-441A-B048-CDE664B7486D
language of work or name	English
author name string	wds:Q60156373-38640F8D-7F6F-4E85-A0C8-E696B4720448
author name string	WILLIAM K. OH
rdfs:label	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS (en) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS (nl)
skos:prefLabel	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS (en) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS (nl)
name	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS (en) MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS (nl)
author	wds:Q60156373-31DF29FE-FCCB-4612-8339-BCB3872AF226
author	Philip W. Kantoff
title	wds:Q60156373-00557DD9-69A0-41FA-A415-C4F244539C2C
title	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS (en)
page(s)	wds:Q60156373-14279951-F95A-42F7-A26B-3BAA16996167
page(s)	1220-1229
instance of	wds:Q60156373-6E24F7E7-91B7-44C3-809A-97DCFF0433EC
instance of	scholarly article
main subject	wds:Q60156373-4BA12082-A00F-4611-BDA9-0624666C325B wds:Q60156373-688B04C9-BE7D-49B0-918E-DB65F460BEFC
main subject	prostate cancer urology
published in	wds:Q60156373-65D91054-98B6-4617-8201-07E184C2B91B
published in	Journal of Urology
issue	wds:Q60156373-6EDAB047-79B4-4F3A-AC3A-C35F1FB1D457
volume	wds:Q60156373-65AD0DE8-D3EC-434A-9066-0C696EF5B0DC
issue	4
volume	160
DOI	wds:Q60156373-F918F318-7F23-42B6-86B8-3FEC4EA0E7A0
DOI	http://dx.doi.org/10.1016/S0022-5347(01)62501-1
DOI	10.1016/S0022-5347(01)62501-1
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q60156373
is cites work of	Secondary hormonal therapies in the treatment of prostate cancer. Peptide analogs in the therapy of prostate cancer. Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer Prostate-specific targeting using PSA promoter-based lentiviral vectors Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells Therapeutic options for hormone-refractory prostate cancer in 2007. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor Clinical conduct and nursing quality of life in prostate cancer Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer Chemotherapy for prostate cancer. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215 Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? The Evolving Role of Docetaxel in the Management of Androgen Independent Prostate Cancer The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer New treatment approaches for prostate cancer based on peptide analogues Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma Development of dendritic-cell based prostate cancer vaccine The potential role of bisphosphonates in prostate cancer Efficacy of irradiation and external hyperthermia in locally advanced, hormone-refractory or radiation recurrent prostate cancer: A preliminary report Anti-androgens and other hormonal therapies for prostate cancer Effects of the luteinising hormone-releasing hormone (LH-RH) agonist leuprolide on adenylyl cyclase regulation through G-protein coupled receptors in rat ventral prostate Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer Recommandations en Onco-Urologie 2010 : Cancer de la prostate Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study Phase II study of vinorelbine in patients with androgen-independent prostate cancer Ethanol extract of Remotiflori radix induces endoplasmic reticulum stress-mediated cell death through AMPK/mTOR signaling in human prostate cancer cells Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity Discovery of LHRH and development of LHRH analogs for prostate cancer treatment Cancer de la prostate Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer. New treatment strategies in advanced prostate cancer Hormone-refractory prostate cancer. Modifications of the therapeutic strategies since chemotherapy proved its usefulness
is cites work of	wds:Q33970538-8A0F1958-FC43-4FC3-A999-AB7CB6798564 wds:Q34348302-9FF294E6-A8B4-451F-9ACB-8F79CA8621A7 wds:Q30792328-DC65729F-939D-4DE5-88FC-E10905CF6D35 wds:Q35553616-28CA046A-31C8-4218-933E-6F9CA8BF229D wds:Q36934785-6247AC26-51AD-4DBB-BDE5-DF50CB91DC1D wds:Q37059390-842A30F6-E626-44D1-A3E2-CA56489C074C wds:Q43566898-45DA0A83-D649-4E8C-9FCC-280A6C264995

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software